KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Research & Development (2016 - 2026)

NovoCure's Research & Development history spans 13 years, with the latest figure at $58.3 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 8.48% to $58.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $229.1 million, a 8.16% increase, with the full-year FY2025 number at $224.5 million, up 7.11% from a year prior.
  • Research & Development hit $58.3 million in Q1 2026 for NovoCure, down from $60.9 million in the prior quarter.
  • Over the last five years, Research & Development for NVCR hit a ceiling of $60.9 million in Q4 2025 and a floor of $42.2 million in Q1 2022.
  • Historically, Research & Development has averaged $54.2 million across 5 years, with a median of $54.3 million in 2023.
  • Biggest five-year swings in Research & Development: skyrocketed 41.36% in 2023 and later fell 13.58% in 2024.
  • Tracing NVCR's Research & Development over 5 years: stood at $54.8 million in 2022, then decreased by 0.93% to $54.3 million in 2023, then decreased by 5.7% to $51.2 million in 2024, then rose by 18.93% to $60.9 million in 2025, then dropped by 4.22% to $58.3 million in 2026.
  • Business Quant data shows Research & Development for NVCR at $58.3 million in Q1 2026, $60.9 million in Q4 2025, and $54.0 million in Q3 2025.